World's Best Scientists 2026 revealed!
Award Badge
Medicine
UK
2026

D-Index & Metrics

Medicine

D-Index
159
Citations
125314
World Ranking
803
National Ranking
85

Research.com Recognitions

  • 2026 - Research.com Medicine in United Kingdom Leader Award
  • 2025 - Research.com Medicine in United Kingdom Leader Award
  • 2023 - Research.com Medicine in United Kingdom Leader Award

Overview

Johann S. de Bono is affiliated with the Institute of Cancer Research in the United Kingdom and has contributed extensively to the field of cancer research, particularly in prostate cancer treatment and molecular oncology. Their research spans multiple domains within medicine and life sciences, showing a strong emphasis on integrating molecular biology with clinical applications.

The main fields of study in their work are Medicine and Biochemistry, Genetics and Molecular Biology. Within these, their subfields of focus include Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, and Cancer Research.

The main research topics covered in their publications reflect a concentration on several key areas:

  • Prostate Cancer Treatment and Research
  • Cancer Immunotherapy and Biomarkers
  • Radiopharmaceutical Chemistry and Applications
  • PARP inhibition in cancer therapy
  • Cancer, Lipids, and Metabolism
  • Cancer Genomics and Diagnostics
  • DNA Repair Mechanisms

Their recent and notable publications include:

  • "Pan-cancer analysis of whole genomes," 2020, Nature
  • "Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer," 2021, New England Journal of Medicine
  • "Olaparib for Metastatic Castration-Resistant Prostate Cancer," 2020, New England Journal of Medicine
  • "Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer," 2020, New England Journal of Medicine
  • "Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019," 2020, European Urology

Johann S. de Bono collaborates frequently with several researchers, reflecting an active role in academic networks. Frequent co-authors include Karim Fizazi, Bora Gürel, Adam Sharp, Suzanne Carreira, and Charles Schloss.

Their work appears regularly in a set of established publication venues, which include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancer Research
  • European Urology
  • Clinical Cancer Research

Best Publications

  • Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

    Howard I. Scher;Karim Fizazi;Fred Saad;Mary-Ellen Taplin

  • Abiraterone and Increased Survival in Metastatic Prostate Cancer

    Johann S. de Bono;Christopher J. Logothetis;Arturo Molina;Karim Fizazi

  • Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

    Peter C Fong;David S Boss;Timothy A Yap;Andrew Tutt

  • Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

    Johann Sebastian De Bono;Stephane Oudard;Mustafa Ozguroglu;Steinbjørn Hansen

  • Integrative clinical genomics of advanced prostate cancer

    Dan Robinson;Eliezer M. Van Allen;Eliezer M. Van Allen;Yi Mi Wu;Nikolaus Schultz

  • Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

    Tomasz M Beer;Andrew J Armstrong;Dana E Rathkopf;Yohann Loriot

  • Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

    Charles J. Ryan;Matthew R. Smith;Johann S. De Bono;Arturo Molina

  • Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

    Johann S. de Bono;Howard I. Scher;R. Bruce Montgomery;Christopher Parker

  • DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

    Joaquin Mateo;Suzanne Carreira;Shahneen Sandhu;Susana Miranda

  • Olaparib for metastatic castration-resistant prostate cancer

    Johann de Bono;Joaquin Mateo;Karim Fizazi;Fred Saad

  • Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

    Nicholas D. James;Johann S. de Bono;Melissa R. Spears;Noel W. Clarke

  • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

    Nicholas D. James;Nicholas D. James;Matthew R. Sydes;Noel W. Clarke;Malcolm David Mason

  • Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

    Colin C. Pritchard;Joaquin Mateo;Michael F. Walsh;Navonil De Sarkar

  • Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

    Georgios Vlachogiannis;Somaieh Hedayat;Alexandra Vatsiou;Yann Jamin

  • Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

    Oliver Sartor;Johann de Bono;Kim N Chi;Karim Fizazi

  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano

  • Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

    Karim Fizazi;Howard I. Scher;Arturo Molina;Christopher J. Logothetis

  • Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

    Peter C. Fong;Timothy A. Yap;David S. Boss;Craig P. Carden

  • Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

    Charles J. Ryan;Matthew R. Smith;Karim Fizazi;Fred Saad

  • Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

    Gerhardt Attard;Alison H.M. Reid;Timothy A. Yap;Florence Raynaud

Frequent Co-Authors

Gerhardt Attard
Gerhardt Attard University College London
Karim Fizazi
Karim Fizazi University of Paris-Saclay
Howard I. Scher
Howard I. Scher Memorial Sloan Kettering Cancer Center
Fred Saad
Fred Saad University of Montreal
Stan B. Kaye
Stan B. Kaye Royal Marsden NHS Foundation Trust
Cora N. Sternberg
Cora N. Sternberg Cornell University
Arturo Molina
Arturo Molina Sutro Biopharma
Celestia S. Higano
Celestia S. Higano University of Washington
Eric J. Small
Eric J. Small University of California, San Francisco
Matthew R. Smith
Matthew R. Smith Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career isn’t limited to becoming a doctor. Online education offers several flexible and in-demand healthcare pathways. For those without a prior nursing background, direct entry msn programs allow non-nurses to transition quickly into advanced nursing roles, bypassing years of prerequisite study.

If you’re seeking a faster route to enter the nursing workforce, online adn programs for non nurses provide accessible entry-level options without requiring previous experience. Many institutions also cater to students who want to avoid standardized test barriers; for instance, you can find a nursing school that doesn't require teas or HESI exams.

An alternative pathway is administrative healthcare. Those interested in behind-the-scenes roles should consider accredited medical billing and coding schools with financial aid, where you can embark on a respected career supporting healthcare providers.

Overall, online healthcare degrees present diverse opportunities for both clinical and non-clinical roles, making it easier to find a pathway that matches your interests and background.

Best Scientists Citing Johann S. de Bono

Trending Scientists

Recently Published Articles